Drug Trial Radar · NCT05831176
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
22
Actual
Start
May 3, 2023
Primary completion
Feb 23, 2026
Study completion Nov 25, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Apr 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the effect of dupilumab on relieving EoG (with or without EoD) symptoms and reducing inflammation in the stomach and, if applicable, small intestine in adults and adolescents aged 12 years and older after at least 24 weeks (about 6 months) and up to 52 weeks (1 year) of treatment. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Eosinophilic Gastritis (EoG)
- Eosinophilic Duodenitis (EoD)
- Eosinophilic Gastrointestinal Disease (EGID)
- Eosinophilic Gastroenteritis
Interventions
DupilumabDrug
Administered as described in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)Time frame: Baseline up to 24 Weeks
Locations
53 sites in 4 countries. Site status is shown where the registry gives one.
Phoenix Childrens Hospital
Phoenix, Arizona
Om Research LLC
Apple Valley, California
Scripps Clinic
La Jolla, California
Om Research LLC
Lancaster, California
University of California - Los Angeles (UCLA)
Los Angeles, California
University of Southern California Keck School of Medicine
Los Angeles, California
GastroIntestinal BioSciences
Los Angeles, California
United Medical Doctors
Murrieta, California
Ucsf Medical Center (Benioff Childrens Hospital)
San Francisco, California
University of Colorado Anschutz Health Science Building (AHSB) CU Research Pharmacy
Aurora, Colorado
Connecticut Clinical Research Institute
Bristol, Connecticut
UConn Health
Farmington, Connecticut
Encore Borland-Groover Clinical Research
Jacksonville, Florida
Northwestern University
Chicago, Illinois
University Of Kansas
Kansas City, Kansas
Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
MNGI Digestive Health P.A.
Plymouth, Minnesota
Mayo Clinic Hospital Rochester
Rochester, Minnesota
Advanced Research Institute
Reno, Nevada
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Northwell Health
Great Neck, New York
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Charlotte Gastroenterology & Hepatology, PLLC
Charlotte, North Carolina
Duke University
Durham, North Carolina
ESI Medical Research, PLLC
Kinston, North Carolina
University of Cincinnati Medical Center-Children's Hospital Medical Center
Cincinnati, Ohio
Ohio State University Medical Center
Columbus, Ohio
Allergy, Asthma and Clinical Research Center
Oklahoma City, Oklahoma
The Oregon Clinic - Gastroenterology East
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
TDDC dba GI Alliance Research
Mansfield, Texas
University of Utah
Salt Lake City, Utah
Seattle Children's Home Health Company
Seattle, Washington
Froedtert Hospital
Milwaukee, Wisconsin
Stollery Children's Hospital - University of Alberta
Edmonton, Alberta, Canada
U.O. Di Ematologia-Azienda Policlinico Consorziale, Ospedaliero-Universitaria, Ospedale
Bari, Italy
Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - Centro Clinico Nemo (Neuro Muscular Omnicentre)
Milan, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.